Big pharma still needs additional late-stage obesity drug assets. Viking's obesity pipeline could attract major pharmaceutical acquisition interest.
| Quartal / Datum | EPS (USD) | Schätzung (USD) | Abweichung |
|---|
| Quartal / Datum | Umsatz (Mrd USD) | Schätzung (Mrd USD) | Abweichung |
|---|